Screener
Avalo Therapeutics AVTX Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Research and development | 23,418 | 14,074 | 37,466 | 23,195 |
| General and administrative | 8,099 | 5,242 | 14,953 | 10,789 |
| Total operating expenses | 31,517 | 19,316 | 52,419 | 33,984 |
| Loss from operations | (31,517) | (19,316) | (52,419) | (33,984) |
| Other (expense) income: | ||||
| Change in fair value of derivative liability | (1,010) | (2,530) | (530) | (2,150) |
| Change in fair value of contingent consideration | (6,574) | — | (6,574) | — |
| Interest income, net | 2,761 | 1,097 | 3,564 | 2,244 |
Item 1. Financial Statements.
FAQ
- What is Avalo Therapeutics's operating income?
- Avalo Therapeutics (AVTX) reported operating income of -$31.52M in Q2 2026.
- How has Avalo Therapeutics's operating income changed year-over-year?
- Avalo Therapeutics's operating income decreased by 63.2% year-over-year, from -$19.32M to -$31.52M.
- What is the long-term trend for Avalo Therapeutics's operating income?
- Over 4 years (2021 to 2025), Avalo Therapeutics's operating income has grown at a -2.9% compound annual growth rate (CAGR), from -$82.14M to -$72.93M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Avalo Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude